Studies have found that in low-risk populations, the severity of myocardial damage caused by PCI is usually not sensitive to the level of platelet P2Y12 inhibition.[30] Low-dose ticagrelor used in patients with stable coronary heart disease undergoing elective PCI treatment has a stronger and longer-lasting platelet inhibition rate, and does not significantly affect the absorption of intracellular adenosine and the level of circulating adenosine, nor affect the release of troponin after PCI. The gene discussed is P2RY12; the disease is coronary artery disorder.